오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg (equivalent: rivastigmine, qty 6 mg) - capsule, hard - excipient ingredients: iron oxide red; hypromellose; gelatin; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; magnesium stearate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; potassium hydroxide; ammonia; pharmaceutical glaze - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - rivastigmine hydrogen tartrate - capsule - 3mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - rivastigmine hydrogen tartrate - capsule - 4.5mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - rivastigmine hydrogen tartrate - capsule - 6mg

유럽 연합 - 영어 - EMA (European Medicines Agency)

actavis group ptc ehf - rivastigmine hydrogen tartrate - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg - capsule - excipient ingredients: iron oxide yellow; stearic acid; microcrystalline cellulose; titanium dioxide; gelatin; iron oxide red; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg - capsule - excipient ingredients: gelatin; titanium dioxide; iron oxide yellow; iron oxide red; maize starch; microcrystalline cellulose; stearic acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg - capsule - excipient ingredients: gelatin; stearic acid; maize starch; iron oxide yellow; microcrystalline cellulose; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg - capsule - excipient ingredients: stearic acid; gelatin; maize starch; titanium dioxide; iron oxide yellow; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg - capsule - excipient ingredients: stearic acid; titanium dioxide; iron oxide yellow; maize starch; gelatin; microcrystalline cellulose; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type